Transaction overview
Rachel Humphrey, a member of the board of directors at Pyxis Oncology, Inc. (NASDAQ: PYXS), reported three separate equity sales in April 2025 in a Form 4 filing with the Securities and Exchange Commission. The trades occurred on April 14, April 17 and April 21, and were all identified with transaction code "S." The combined proceeds from the three dispositions amounted to $15,917.
Details of the sales
- On April 14, 2025, Humphrey sold 1,400 shares at a weighted average price of $0.9727, with individual trade prices ranging from $0.97 to $0.98.
- On April 17, 2025, she sold 200 shares at a price of $0.97.
- On April 21, 2025, Humphrey sold 13,896 shares at a weighted average price of $1.0335, with reported transaction prices ranging from $0.97 to $1.09.
Post-transaction holdings and trading framework
Following the April transactions, Humphrey is recorded as directly owning 81,309 shares of Pyxis Oncology. The sales were carried out under a Rule 10b5-1 trading arrangement that Humphrey adopted on December 5, 2024, according to the filing.
Market context and valuation note
At the time of the filing and related reporting, Pyxis Oncology's stock was trading at $1.43, representing an approximate 11% decline over the previous week. InvestingPro analysis referenced in the filing suggests the company remains undervalued at current levels.
Clinical-development and analyst activity
Separately from the insider transactions, Pyxis Oncology has been the subject of recent analyst commentary tied to its MICVO candidate and ongoing dose-expansion work. The company has met its enrollment objective for the monotherapy dose-expansion cohorts, reaching a target of 40 patients in the study focused on second-line or later recurrent/metastatic head and neck squamous cell carcinoma. The enrolled cohort includes patients with prior exposure to EGFR inhibitors and PD-1 therapies, as well as those experienced with platinum-based chemotherapy and PD-1 treatments.
Several investment banks and research firms issued updates and price-target revisions in light of the trial activity and anticipated data. H.C. Wainwright and Guggenheim reiterated Buy ratings with $7.00 price targets and highlighted that phase 1 data is expected in mid-2026. Jefferies raised its price target to $8.00 from $7.40 while maintaining a Buy rating based on drug data the firm found encouraging. Stifel adjusted its price target down from $9.00 to $8.00, citing financing assumptions but retained a Buy rating. William Blair reiterated a Market Perform rating and noted the rapid pace of enrollment in the dose-expansion study.
What the filing shows - and what it does not
The Form 4 documents the timing, quantities, and prices of the three April trades and confirms that the sales were executed under a pre-established trading plan. Beyond those mechanics and the firm's clinical and analyst updates, the filing does not provide additional commentary from the director or management on motives or future insider activity.
This report is focused on the disclosure of insider transactions, the director's remaining holdings, the mechanics of the 10b5-1 plan, recent clinical enrollment milestones and the suite of analyst ratings and price-target movements tied to Pyxis Oncology's MICVO program.